JUNO Therapeutics Inc (JUNO); Coherus Biosciences Inc (CHRS), Stemline Therapeutics Inc (STML): VCHP’s Bullish Sentiment Pays Off

Page 2 of 2

Coherus Biosciences Inc (NASDAQ:CHRS) is another stock VHCP Management is bullish on. Last quarter, the investment firm initiated a stake in the company with the purchase of 870,300 shares, valued at $13.07 million. Joseph Edelman’s Perceptive Advisors also holds a considerable stake in the company, amounting to 438,000 shares. Coherus Biosciences Inc (NASDAQ:CHRS) went public in November and  since its IPO, the stock has already gained an impressive 126% and is trading at $28.98 as of Thursday afternoon. The stock could continue to climb in the near future, since the company is set to announce its earnings results for this quarter on Monday. Furthermore, last month, analysts at JPMorgan raised their price target for Coherus Biosciences Inc (NASDAQ:CHRS) to $35.00 per share from $20.00.

Finally, VHCP Management is also bullish regarding Stemline Therapeutics Inc (NASDAQ:STML), holding 356,400 shares, after increasing its exposure to the stock by more than 400% last quarter. Although the company’s share price plummeted by 33.5% over the past 52-weeks, the stock gained 28.6% over the past six months. Hence, after dropping to a 52-week low of $10.50 per share during the third quarter, Stemline Therapeutics Inc (NASDAQ:STML) seems to be bouncing back. The company is set to deliver its quarterly earnings results soon and according to numerous analysts, the results should be optimistic. In addition to VHCP Management, numerous hedge funds are bullish on the stock, such as Julian Baker and Felix Baker’s Baker Bros. Advisors, which own 338,700 shares. Israel Englander’s Millennium Management is also betting on Stemline Therapeutics Inc (NASDAQ:STML), with a stake of 163,400 shares.

Tracking the activity of hedge funds is a great way to find new investment opportunities, especially when it comes to small-cap stocks such as the ones presented above. Since these equities offer investors far greater profit margins, we have devised a small-cap strategy that consists of analyzing hedge fund filings and seeking out their most profitable investments. Furthermore, since hedge fund managers charge around 35% of profits made as fees, you can generate far better returns by investing directly in the best-performing stocks chosen by major investment firms. Hence, it is worth paying attention to our strategy that returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012. By following this strategy, investors will be able to beat the market and avoid the exorbitant fees charged by hedge funds.

Disclosure: none.

Page 2 of 2